258 related articles for article (PubMed ID: 38502417)
1. Novel Therapeutic Targets in Acute Myeloid Leukemia (AML).
Wysota M; Konopleva M; Mitchell S
Curr Oncol Rep; 2024 Apr; 26(4):409-420. PubMed ID: 38502417
[TBL] [Abstract][Full Text] [Related]
2. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
3. New and emerging therapies for acute myeloid leukaemia.
Davis JR; Benjamin DJ; Jonas BA
J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia.
Kropp EM; Li Q
Exp Hematol; 2022 Jul; 111():13-24. PubMed ID: 35417742
[TBL] [Abstract][Full Text] [Related]
5. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
6. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract][Full Text] [Related]
7. Novel treatments for relapsed/refractory acute myeloid leukemia with
Tallis E; Borthakur G
Expert Rev Hematol; 2019 Aug; 12(8):621-640. PubMed ID: 31232619
[No Abstract] [Full Text] [Related]
8. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
9. Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia.
Obszański P; Kozłowska A; Wańcowiat J; Twardowska J; Lejman M; Zawitkowska J
Molecules; 2022 Jun; 27(12):. PubMed ID: 35745032
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the understanding and treatment of acute myeloid leukemia.
Watts J; Nimer S
F1000Res; 2018; 7():. PubMed ID: 30135719
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
[TBL] [Abstract][Full Text] [Related]
12. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
13. New Treatment Options for Acute Myeloid Leukemia in 2019.
Cerrano M; Itzykson R
Curr Oncol Rep; 2019 Feb; 21(2):16. PubMed ID: 30715623
[TBL] [Abstract][Full Text] [Related]
14. The dual role of autophagy in acute myeloid leukemia.
Seo W; Silwal P; Song IC; Jo EK
J Hematol Oncol; 2022 May; 15(1):51. PubMed ID: 35526025
[TBL] [Abstract][Full Text] [Related]
15. Approach to the Older Patient with Acute Myeloid Leukemia.
Zimmer M; Kadia T
Curr Oncol Rep; 2023 Nov; 25(11):1203-1211. PubMed ID: 37688738
[TBL] [Abstract][Full Text] [Related]
16. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
[TBL] [Abstract][Full Text] [Related]
17. Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future.
Choi JH; Shukla M; Abdul-Hay M
Acta Haematol; 2023; 146(6):431-457. PubMed ID: 37459852
[TBL] [Abstract][Full Text] [Related]
18. FLT4 as a marker for predicting prognostic risk of refractory acute myeloid leukemia.
Lee JY; Lee SE; Han AR; Lee J; Yoon YS; Kim HJ
Haematologica; 2023 Nov; 108(11):2933-2945. PubMed ID: 37317880
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.
Wang N; He J; Liu F
Chemotherapy; 2022; 67(3):178-182. PubMed ID: 35306492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
